Relmada reports FY 2023 net loss of $98.8M; advancing Phase 3 MDD trials with data expected H2 2024

RELMADA THERAPEUTICS, INC.

Q4 2023 net loss $25.2M ($0.84/share) vs $37.9M ($1.28) in Q4 2022; full-year net loss $98.8M ($3.28/share).
Cash, equivalents and short-term investments at Dec 31, 2023: $96.3M, down from $148.3M a year earlier.
R&D expense fell to $54.8M in FY 2023 from $113.3M in FY 2022, reflecting completion of prior Phase 3 trials.
REL-1017 Phase 3 Reliance II enrollment on track; top-line data expected H2 2024; Relight enrollment targeted by year-end 2024.
REL-P11 psilocybin Phase 1 in obese patients expected H1 2024; Phase 2a proof-of-concept data seen H1 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: $98.8 million
EPS: $3.28 per basic and diluted share
Result: preliminary results

Exact text from the filing

Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2023. (These results are preliminary and unaudited.)

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: $98.8 million
EPS: $3.28 per basic and diluted share
Result: preliminary results

Exact text from the filing

Net loss for the year ended December 31, 2023 and 2022 was $98.8 million and $157.0 million, respectively. The Company had a net loss of $3.28 and $5.30 per basic and diluted share for the year ended December 31, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-024022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.